Terns Pharmaceuticals Stock Alpha and Beta Analysis
| TERN Stock | USD 5.79 0.08 1.40% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Terns Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Terns Pharmaceuticals over a specified time horizon. Remember, high Terns Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Terns Pharmaceuticals' market risk premium analysis include:
Beta 1.22 | Alpha (0.50) | Risk 5.06 | Sharpe Ratio (0.07) | Expected Return (0.37) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Terns |
Terns Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Terns Pharmaceuticals market risk premium is the additional return an investor will receive from holding Terns Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Terns Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Terns Pharmaceuticals' performance over market.| α | -0.5 | β | 1.22 |
Terns Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Terns Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Terns Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Terns Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Terns Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Terns Pharmaceuticals shares will generate the highest return on investment. By understating and applying Terns Pharmaceuticals stock market price indicators, traders can identify Terns Pharmaceuticals position entry and exit signals to maximize returns.
Terns Pharmaceuticals Return and Market Media
The median price of Terns Pharmaceuticals for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 7.62 with a coefficient of variation of 15.77. The daily time series for the period is distributed with a sample standard deviation of 1.23, arithmetic mean of 7.81, and mean deviation of 0.94. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Terns Announces Pricing of Upsized 150.15 Million Public Offering | 09/11/2024 |
2 | Terns Pharmaceuticals director buys 5 million in company stock | 09/17/2024 |
3 | This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lillys Weight-Loss Treatments | 09/18/2024 |
4 | Terns Pharmaceuticals Obesity Advancement Continues With Other Q1 2025 Program Catalyst - Seeking Alpha | 09/25/2024 |
5 | Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 | 10/07/2024 |
6 | Tern Shares Down 41.5 percent Whats Next | 10/17/2024 |
7 | Iain Ross Buys 1,100,000 Shares of Tern Plc Stock | 11/01/2024 |
8 | Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates | 11/12/2024 |
9 | What is HC Wainwrights Forecast for TERN FY2024 Earnings | 11/15/2024 |
10 | Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors | 11/18/2024 |
11 | Telemark Asset Management LLC Purchases Shares of 300,000 Terns Pharmaceuticals, Inc. - MarketBeat | 11/22/2024 |
About Terns Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Terns or other stocks. Alpha measures the amount that position in Terns Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | PB Ratio | 1.11 | 1.32 | 1.81 | 1.72 | Capex To Depreciation | 0.66 | 0.27 | 0.059 | 0.0561 |
Terns Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Terns Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Terns Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Terns Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Terns Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Terns Pharmaceuticals' management manipulating its earnings.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Terns Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Terns Pharmaceuticals Backtesting, Terns Pharmaceuticals Valuation, Terns Pharmaceuticals Correlation, Terns Pharmaceuticals Hype Analysis, Terns Pharmaceuticals Volatility, Terns Pharmaceuticals History and analyze Terns Pharmaceuticals Performance. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Terns Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.